Bionano Genomics Inc. (BNGO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX 
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago.
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Monday
Bionano Genomics (NASDAQ: BNGO - Get Free Report) is anticipated to post its Q4 2025 results after the market closes on Monday, March 23rd. Analysts expect Bionano Genomics to post earnings of ($0.81) per share and revenue of $7.88 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Robert Erik Holmlin - President, CEO, CFO & Director Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Kelly Gura - Unidentified Company Investor Relations - Unidentified Company Operator Good day, and welcome to the Bionano Second Quarter 2025 Earnings Conference Call.
Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Vivian Alhorn - BTIG Joanne Lee - Maxim Group Operator Good day, and welcome to the Bionano First Quarter 2025 Earnings Conference Call. Today's conference is being recorded.
Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano Fourth Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
